207 results about "Hydroxybutyric acid" patented technology

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The invention provides a bio-based 1, 4-butanediol composition as well as a preparation method and application thereof, and the bio-based 1, 4-butanediol composition comprises bio-based 1, 4-butanediol, 4-hydroxybutyric acid-(4-hydroxyl) butyl ester and bis (4-hydroxyl) dibutyl ether. The total mass content of 4-hydroxybutyric acid-(4-hydroxyl) butyl ester and bis (4-hydroxyl) dibutyl ether in the bio-based 1, 4-butanediol composition is 51 to 220 ppm. The bio-based 1, 4-butanediol composition has low hygroscopicity, and can maintain low water content after long-term storage; meanwhile, when the bio-based 1, 4-butanediol composition is used for polyester synthesis, the esterification time can be shortened, the reaction efficiency can be improved, side reactions can be reduced, and a polyester product with better damp-heat resistance stability can be obtained.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

The invention provides a composite quality control liquid for an electrochemical multi-parameter detector. The composite quality control liquid comprises a buffer volume, a quality control substance and a stabilizer, the stabilizing agent comprises 5 to 50 g / L of bovine serum albumin, 0.1 to 10 g / L of EDTA-2Na (Ethylene Diamine Tetraacetic Acid), 10 to 100 g / L of a viscosity regulator, 0.3 to 25 g / L of a preservative and 5 to 20 g / L of a surfactant; the preparation method comprises the following steps: adding components of the stabilizer into a buffer system, preparing a preparation solution, preparing mother liquor of each quality control substance, proportionally mixing glucose mother liquor, uric acid mother liquor, beta-hydroxybutyric acid mother liquor and cholesterol sodium sulfate and triglyceride composite mother liquor according to the target concentration of the quality control solution, and fixing the volume by using the preparation solution to obtain the quality control liquid. And fully and uniformly mixing to obtain the composite quality control liquid. The composite quality control liquid can ensure that uric acid is not degraded, cholesterol triglyceride is not separated out, the formula is mild, and active substances in a detection system are not influenced.

The invention relates to the field of bio-based composite materials, and discloses a bioplastic-based coupling agent, a modified bamboo fiber, a composite material and a preparation method and application of the bioplastic-based coupling agent and the modified bamboo fiber. The coupling agent is a product obtained by modifying polyhydroxybutyrate valerate and a grafting monomer, and the grafting monomer is at least one of maleic anhydride, acrylic acid or itaconic anhydride. The delignification bamboo powder is modified with the coupling agent, and the modified bamboo fiber, polyhydroxybutyrate-hydroxyvalerate, an initiator and an auxiliary agent are subjected to melt blending to obtain the composite material. The tensile strength and the bending strength of the composite material are respectively improved by 175% and 117%, and the crystallization ability and the thermal stability are also synchronously improved. According to the invention, the unification of high strength, thermal stability and excellent interfacial compatibility is realized while the degradability of the system is maintained, and the composite material has a good green composite material application prospect.

The invention relates to the technical field of polyester degradable plastics, and discloses a biodegradable shrink film as well as a preparation method and application thereof. The preparation method of the biodegradable shrink film comprises the following steps: reacting (R)-3-hydroxybutyric acid with 1, 4-dibromobutane to obtain a dihydric alcohol monomer; the preparation method comprises the following steps: copolymerizing a dihydric alcohol monomer and L-lactide to obtain modified polylactic acid; carrying out copolymerization on the geraniol-based compound and L-lactide to obtain a bio-based plasticizer; modifying the bio-based plasticizer with allyl trimethyl ammonium chloride to obtain a modified bio-based plasticizer; the biodegradable shrink film is prepared by taking modified polylactic acid, poly (butylene adipate-co-terephthalate), a modified bio-based plasticizer, a functional filler and palm wax as raw materials. The biodegradable shrink film has the advantages of flexibility, shrinkage performance, lasting antibacterial performance and good barrier performance, and can be used in food packaging materials.

The invention provides a method for preparing (R)-4-chloro-3-hydroxybutyric acid ethyl ester ((R)-CHBE) through enzyme catalysis, which comprises the following steps: isopropanol is used as a hydrogen donor, a ketoreductase mutant is used for carrying out catalytic reduction reaction of COBE to prepare (R)-CHBE, and the ketoreductase mutant has amino acid mutation at the 83rd site on the basis of an amino acid sequence shown as SEQ ID NO.1. The invention also provides a preparation method of (R)-4-chloro-3-hydroxybutyric acid ethyl ester ((R)-CHBE). The thermal stability, namely heat resistance, of the ketoreductase mutant is improved, and by combining with the use of a rectifying tower, the method disclosed by the invention improves the utilization rate of isopropanol and can discharge a byproduct acetone in time, so that the substrate conversion rate and the product concentration are improved. The invention also provides an enzyme catalysis device used in the method.

The present application relates to the technical field of surface treatment, in particular to a kind of biobased degradable cable material and preparation method thereof.Biobased degradable cable material includes 55-65 parts of poly-L-lactic acid and poly-3-hydroxybutyric acid-3-hydroxyhexanoate mixed matrix resin, 4-6 parts of dianhydride modified castor oil polyol, 10-15 parts of polyaminoval, 5-8 parts of nano enhanced filler, 6-10 parts of biobased plasticizer, 0.5-1.0 parts of antioxidant, 8-12 parts of environmentally friendly flame retardant.Dynamic ester bond crosslinking agent dianhydride modified castor oil polyol reaction forms dynamic ester bond crosslinking network, ester bond breakage occurs at high temperature beyond normal working range to release stress, temperature returns to normal and can recombine again;Semi-interpenetrating network enhanced phase polyaminoval forms interpenetrating structure with matrix resin in molecular chain interlacing mode, constructs stable heat-resistant skeleton, effectively inhibits high-temperature deformation, and its biobased structure ensures the overall degradability of the material, realizes the balance of heat resistance and degradability.

The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids, chlorogenic acid, and, optionally, ketones are disclosed. The compositions include one or more short chain fatty acids (such as butyric acid, butyrate salts, propionic acid, propionate salts, acetic acid, or acetate salts); chlorogenic acid; and, optionally, one or more beta-hydroxybutyrate salts. The compositions and methods are useful for inducing ketosis and / or beta-oxidative activity in a subject. In addition, compositions that include concentrated forms of, and methods of using, chlorogenic acid (alone or in combination with short chain fatty acids and ketones) to induce ketogenesis in a subject are disclosed.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

A method of improving flavor of a combination of a composition for increasing circulating ketone levels is disclosed. A composition containing (D)-β-hydroxybutyric acid (D-BHB), (D)-β-hydroxyvaleric acid (D-BHV), and (D)-1,3 butanediol (D-1,3BD) is disclosed. Exemplary compositions may be incorporated into food, supplement, and beverage products.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

The invention relates to the technical field of biological materials, in particular to 4-hydroxybutyrate coenzyme A transferase and application thereof. The 4-hydroxybutyrate coenzyme A transferase has an amino acid sequence as shown in SEQ ID NO: 1. According to the 4-hydroxybutyric acid coenzyme A transferase provided by the embodiment of the invention, the proportion of 4-hydroxybutyric acid or 3-hydroxyhexanoic acid in PHA synthesized by eutrophus Rosei and halomonas can be remarkably increased. The engineering modified bacterium containing the 4-hydroxybutyric acid coenzyme A transferase provided by the embodiment of the invention can realize the PHA content of 8.58 g / L, and the molar ratio of 4-hydroxybutyric acid is as high as 46.4%.

The invention provides a method for synthesizing ethyl 4-cyano-3-hydroxybutyrate by a pure hydrocyanic acid method, which is characterized in that ethyl 4-chloro-3-hydroxybutyrate and hydrocyanic acid are used as raw materials, a biological enzyme is used as a catalyst, the pH value of a reaction solution is controlled to be 6.5-7.5, and the ethyl 4-cyano-3-hydroxybutyrate is synthesized; the hydrogen cyanide is used as a raw material, so that the cost of a sodium cyanide preparation process can be reduced, the consumption of sodium hydroxide can be reduced, and the treatment cost of pollutants (sodium salt) can be reduced. The method has the advantages of being high in reasonability, low in material loss and high in production efficiency. The ethyl 4-cyano-3-hydroxybutyrate prepared by the method has the yield of 80%, the content of more than or equal to 98.5% and the single impurity content of less than 0.5%.

The present application relates to the pharmaceutical use of 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester, in particular to its use in the preparation of a medicament for preventing and / or treating diseases associated with abnormal osteoclast activity. It has been found that 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has a significant inhibitory effect on osteoclast differentiation, and intra-articular injection of 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has a therapeutic effect on MIA-induced osteoarthritis. Therefore, 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has the prospect of being developed into a therapeutic drug for diseases associated with abnormal osteoclast activity.

The invention relates to a process for preparing polyol esters, in particular polyglycerol esters, of 3-hydroxybutyric acid blocked or with terminal acyl groups, to the products that can be obtained in this way and to their functionalized (e.g., esterified) derivatives, as well as to various uses and applications of these products.

Provided is a novel resin composition containing poly(3-hydroxybutyrate) (also referred to as "PHB") and being capable of preventing adhesion to a metal part during fiberization.　The resin composition contains poly(3-hydroxybutyrate) and a polyglycerol unsaturated fatty acid ester.

Provided is a turnover promoter capable of promoting the turnover of epidermis. In the present invention, a turnover promoter for epidermis is prepared, the turnover promoter containing at least one 3-hydroxybutyric acid component selected from 3-hydroxybutyric acid, a salt of 3-hydroxybutyric acid, and a 3-hydroxybutyric acid alkyl ester represented by formula (1) (wherein R represents an alkyl group). The turnover promoter may further contain a skin whitening agent. The skin whitening agent may contain a tyrosinase inhibitor and / or a melanin transport inhibitor.

The invention relates to a hyaluronic acid high-yield strain based on metabolic flow optimization as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. According to the corynebacterium glutamicum, sources of key rate-limiting enzymes UDP-glucose dehydrogenase and glutamine-fructose-6-phosphate aminotransferase are screened, and heterologous expression of hyaluronic acid synthase and overexpression of endogenous inositol permease and glucokinase are combined, so that the corynebacterium glutamicum capable of highly producing hyaluronic acid is constructed in a form of optimizing metabolic flux; according to the invention, the hyaluronic acid is used as a substrate, polyhydroxybutyrate synthase clusters are further overexpressed in the substrate, the glucose uptake and utilization efficiency of a host are improved, the metabolic coupling of cofactors is realized, the yield of the hyaluronic acid reaches 45g / L, the production intensity is 1.25 g / L / h, a brand new tool is provided for the production of the hyaluronic acid, and the method has an excellent application prospect.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The invention discloses an application of R-3-hydroxybutyric acid (R-3-hydroxybutyric acid, 3HB) or a derivative of the R-3-hydroxybutyric acid in delaying and preventing light aging of skin. Experiments prove that the 3HB or the derivative thereof can remarkably improve the skin appearance of a mouse with photoaged skin, improve the antioxidant capacity of skin tissue, remarkably recover the thickness of the epidermal layer and the corium layer of the skin, maintain the collagen content in the skin, reduce the denaturation degree of elastic fibers in the skin and improve the skin aging resistance of the mouse. The obvious effect of delaying and preventing the skin photoaging is achieved. The invention provides a novel skin aging treatment medicine or cosmetic candidate compound which has a wide clinical application prospect and good social and economic benefits.

The present invention relates to a synergistic composition for the treatment of disorders related to central nervous system (CNS) excitability. The synergistic composition comprises combination of GABA receptor agonists and synaptic plasticity enhancer or salts thereof along with pharmaceutically acceptable excipients. The GABA receptor agonists are selected from the group consisting of 4-[(2R)-2,4-Dihydroxy-3,3-dimethylbutanamido]butanoic acid, 4- (Pyridine-3-carbonylamino)butanoic acid and 4-(hexadecanoylamino)butanoic acid or salts thereof. The synaptic plasticity enhancer are selected from magnesium 2- acetamidoethanesulfonate, magnesium bis (2-aminoethane-1-sulfonate), magnesium;(2S,3R)- 2,3,4-trihydroxybutanoate, N-(2-Hydroxyethyl)hexadecanamide, 1-(4-aminobutyl)guanidine and 5'-inosinic acid or salts thereof.

The application discloses a ketoreductase and application of the ketoreductase in preparation of (R)-4-chloro-3-hydroxybutyric acid ethyl ester. The ketoreductase disclosed by the application has an amino acid sequence shown in SEQ ID NO:1, and a mutant of the ketoreductase has an amino acid sequence shown in SEQ ID NO:3. The ketoreductase and the mutant thereof provided by the application can realize efficient catalysis of a reaction of converting 4-chloroacetyl acetic acid ethyl ester into (R)-4-chloro-3-hydroxybutyric acid ethyl ester.

The present invention relates to a recombinant halomonas comprising an exogenously introduced xylose metabolic pathway and a metabolic pathway for synthesizing a copolymer of hydroxybutyric acid (HB) and lactic acid (LA), whereby the copolymer can be synthesized from a xylose-containing cellulose hydrolysate, the LA ratio can be controlled by further promoter modification and process optimization, and industrial enlargement is facilitated.

The invention discloses a preparation method and application of a soft capsule containing (R)-3-hydroxybutyric acid. The preparation method comprises the following steps: S1, mixing an (R)-3-hydroxybutyric acid solution with a porous material, drying and sieving to obtain composite solid powder; wherein the porous material is selected from any one of gel silicon dioxide, porous starch and isomaltitol; s2, adding a thickening agent into an oily solvent, dissolving, then sequentially adding an antioxidant and the composite solid powder, and uniformly mixing to obtain a soft capsule content; and S3, under a heating condition, mixing glycerol, water, gelatin and an opacifying agent, dissolving and defoaming to obtain a capsule skin glue solution, pelleting the capsule skin glue solution and the soft capsule content through a pelleting machine, and drying to obtain the soft capsule. The soft capsule prepared by the method disclosed by the invention can effectively avoid the corrosion effect of (R)-3-hydroxybutyric acid on the capsule shell, is beneficial to improving the stability, and is simple in preparation process and suitable for industrial production.

The invention relates to the technical field of metabolic engineering bacteria. The invention provides an engineering bacterium for improving the yield of poly-beta-hydroxybutyric acid and a construction method of the engineering bacterium. According to the invention, methylotrophic bacteria MB200 is taken as an original strain, a mispairing repair system MutL gene knock-down strain of CRISPRi is constructed, so that the mispairing repair system MutL gene knock-down strain has a higher gene mutation rate, laboratory directed evolution is carried out by utilizing a screening mode of'rich-deficient carbon sources', chassis cells with stable genomes after directed evolution are obtained, and the engineering strain is named as MB-P1. Compared with the original strain methylotrophic bacteria MB200, the PHB production capacity of the MB-P1 is improved by 72.61%. The method provided by the invention is suitable for optimizing the methylotrophic bacteria strain for producing the PHB, provides a new normal form for realizing efficient accumulation of the PHB, and has wide industrial application potential.

The invention relates to the technical field of compatilizers, and particularly discloses a P34HB-g-GMA compatilizer as well as a preparation method and application thereof. The P34HB-g-GMA compatilizer is prepared from the following preparation raw materials in percentage by mass: 88%-98% of poly (3-hydroxybutyrate-4-hydroxybutyrate), 0.02%-2% of an initiator, 1%-10% of glycidyl methacrylate, 0.1%-1% of an inhibitor, 0.1%-1% of a lubricant and 0.1%-1% of an auxiliary agent, wherein the sum of the mass percentages of the preparation raw materials is 100%. The P34HB-g-GMA, which is prepared by carrying out addition reaction on GMA serving as a grafting monomer and free radicals on a P34HB molecular chain, has the property of a compatilizer, and can be used for effectively improving the compatibility between PHA and other biological materials and improving the stability and the mechanical property of the composite material when being applied to a biodegradable composite material.

The application discloses a ketoreductase derived from Schizosaccharomyces japonicus yFS275 and application thereof. The ketoreductase has an amino acid sequence shown in SEQ ID NO:1, and a mutant thereof has an amino acid sequence shown in SEQ ID NO:3. The ketoreductase and the mutant thereof provided by the application can efficiently catalyze the conversion of ethyl 4-chloroacetoacetate into (R)-4-chloro-3-hydroxybutyric acid ethyl ester, and the mutant thereof has higher organic solvent resistance.